药物类型 T细胞疗法 |
别名 allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)、Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes、HSV-Tk + [5] |
靶点- |
作用方式 刺激剂 |
作用机制 细胞替代物、免疫刺激剂 |
在研适应症- |
在研机构- |
非在研机构 |
最高研发阶段撤市 |
最高研发阶段(中国)- |
特殊审评- |
开始日期2009-10-27 |
申办/合作机构 |
开始日期2008-10-01 |
申办/合作机构 |
开始日期2007-06-01 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
血液肿瘤 | 欧盟 | 2016-08-18 | |
血液肿瘤 | 冰岛 | 2016-08-18 | |
血液肿瘤 | 列支敦士登 | 2016-08-18 | |
血液肿瘤 | 挪威 | 2016-08-18 | |
造血干细胞移植 | 欧盟 | 2016-08-18 | |
造血干细胞移植 | 冰岛 | 2016-08-18 | |
造血干细胞移植 | 列支敦士登 | 2016-08-18 | |
造血干细胞移植 | 挪威 | 2016-08-18 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | - | TK-DLI | 鹹觸獵遞鑰齋襯廠壓淵(餘淵壓淵淵積窪網壓簾) = 艱積積憲襯構鑰衊壓醖 顧鏇膚壓繭淵蓋鑰膚壓 (構遞範憲鑰積鹹窪顧簾 ) 更多 | - | 2006-06-20 | ||
N/A | 8 | Tk-DLI | 餘鬱淵鏇製選憲範醖簾(網網選繭鏇襯製艱鏇構) = Multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all signs of GvHD 遞壓鬱衊鹽顧廠襯繭顧 (積齋築襯積範夢淵簾觸 ) 更多 | - | 2004-07-15 | ||
N/A | 8 | 窪鹹鏇觸範繭鑰餘壓鬱(襯網廠蓋選築繭壓壓鹹) = 1/8 patients experienced grade II biopsy-proven acute GvHD, involving the skin and the liver. The administration of multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all clinical and biochemical signs of GvHD. Two patients of this series received unmodified DLI and died of refractory GvHD and disease progression. 選艱夢築醖壓製餘醖壓 (鬱壓鹹夢簾遞淵憲鬱築 ) | 积极 | 2002-05-01 |